Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere Gets FDA OK for C. Difficile Test

NEW YORK (GenomeWeb News) – Nanosphere today said that the US Food and Drug Administration has granted 510(k) clearance for the firm's Clostridium difficile molecular test.

The test, which runs on Nanosphere's Verigene system, detects the toxin A and B gene sequences of C. difficile and identifies the PCR ribotype 027 strain, which is associated with increased severity of disease. The test automates the steps of bacterial DNA extraction, amplification, hybridization, and target detection on the Verigene system.

Nanosphere CEO Bill Moffitt noted in a statement that the firm has had four new products cleared by the FDA in the last 12 months. The other tests are for gram positive bloodstream infections, respiratory viruses, hypercoagulation, and warfarin metabolism.

Nearly 500,000 Americans are infected with C. difficile annually and is linked to more than 30,000 deaths per year in the US, said Nanosphere.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.